Pharmstandard International

What Pharmstandard International does

Pharmstandard International S.A. is a Luxembourg-incorporated société anonyme (founded 8 December 2010) that operates as a dedicated venture investment vehicle for innovative medicine. It is a wholly-owned subsidiary of PJSC Pharmstandard (LSE:PHST), Russia's leading pharmaceutical producer, and is structurally designed to source, acquire, and manage minority equity positions in early- and mid-stage biotechnology companies, then channel successful assets into the Russian market through its parent. The company employs its funds to build and manage a portfolio of securities and patents, participate in the development and control of enterprises, and provide support, loans, advances, or guarantees to portfolio companies.

The company's portfolio — effectively its "products" — comprises eight disclosed biotech investments spanning metabolic and orphan diseases (Allena Pharmaceuticals, ALLN-177), personalized cancer and HIV immunotherapy (Argos Therapeutics, Arcelis platform), mucosal gene delivery for IBD and diabetes (enGene, Canada), T cell checkpoint oncology (Jounce Therapeutics), disulfide-rich peptide drug discovery (Protagonist Therapeutics, US/Australia), kidney and vascular biologics (Proteon Therapeutics), intraoperative cancer imaging (Avelas Biosciences, Nobel-laureate Tsien technology), and ex-vivo organ perfusion for transplantation (TransMedics). Portfolio companies are predominantly US- and Canada-based, with the value proposition being a cross-border bridge between North American biotech innovation and Russian commercialization through the PJSC Pharmstandard distribution apparatus.

The business model is corporate venture capital rather than product sales. Revenue mechanics are not disclosed; the entity is funded entirely by its parent through capital, loans, advances, and guarantees, and it does not employ traditional marketing, pricing, or distribution channels. Customer segments are limited to portfolio companies and the parent group; pricing models and publicly disclosed pricing are unavailable. There is no disclosed headcount; the only named executive is Director Eriks Martinovskis, based at the Luxembourg headquarters at 10A rue Henri Schnadt.

Name

Pharmstandard International

Legal name

Pharmstandard International S.A.

Website

https://pharmstd.lu

Company type

Private

Founded year

2010

Operating status

Operating

Short description

Pharmstandard International S.A. is a Luxembourg-incorporated, wholly-owned venture investment subsidiary of PJSC Pharmstandard (LSE:PHST), Russia's leading pharmaceutical producer. It acquires and manages minority equity stakes in innovative North American biotech companies to channel assets into the Russian market through its parent.

Ownership category

akta.pro rank

Product category

Biotechnology Venture Capital

NAICS

Portfolio Management and Investment Advice (523940)

SIC

Patent Owners & Lessors (6794)

akta.pro primary industry

Corporate LP Programs (Corporate as LP in VC/PE funds) (FSANAHAH)

akta.pro secondary industries

Patent Prosecution & Portfolio Management (BPAHAMAA), Specialty Care Pharmaceuticals (HLAIAAAB)

Keywords

• Venture capital investments
• Biotech portfolio management
• Pharmaceutical innovation financing
• Medicine equity investments
• Healthcare venture funding

Headquarters

HQ city

Luxembourg

HQ country

Luxembourg

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Operations, Personnel, Others

Core offering

Pharmstandard International S.A. is a venture investment company that deploys capital into innovative medicine and biotech companies primarily located in North America. It uses its funds to form and manage a portfolio of securities and patents, participate in the development and control of investee enterprises, and provide support, loans, advances, or guarantees to companies in which it holds participating interests.

Product overview

Pharmstandard International S.A. is a venture capital investment company, not a product company. It operates as a 100% subsidiary of PJSC Pharmstandard (LSE:PHST), focused on investing in innovative medicine with potential in global markets and Russia. The company's 'products' are its investment portfolio companies, which include: Allena Pharmaceuticals (non-systemic oral protein therapeutics), Argos Therapeutics (personalized immunotherapies via Arcelis™ platform), enGene (mucosal immunotherapy platform), Jounce Therapeutics (cancer immunotherapies), Protagonist Therapeutics (disulfide-rich peptides), Proteon Therapeutics (kidney and vascular pharmaceuticals), Avelas Biosciences (cancer surgery technologies), and TransMedics (organ transplantation perfusion systems).

Differentiator

Problem solved

Functional benefit

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators1 record

Recent moves6 records

Expansion highlights4 records

Direct peers

• Bayer Leaps by Bayer: Bayer's venture investment arm focused on biotech and life sciences breakthroughs. Comparable as a major-pharma CVC making direct equity investments in innovative therapeutic platforms.
• Pfizer Ventures: Pfizer's CVC arm investing in emerging biotech companies. Directly comparable as a large-pharma corporate investor in clinical-stage therapeutic developers.
• Roche Venture Fund: Corporate venture arm of Roche focused on early-stage therapeutic and diagnostic investments. Same archetype as Pharmstandard International — pharma-major-backed CVC targeting innovative medicine.
• Amgen Ventures: Corporate venture capital arm of Amgen investing in therapeutic biotech companies. Same archetype of pharma-major-backed early-stage therapeutic investing.
• Boehringer Ingelheim Venture Fund: Corporate VC arm of Boehringer Ingelheim investing in early-stage biotech and therapeutics. Comparable as a major pharma CVC with similar focus on innovative medicine and biotech companies.
• Sanofi Ventures: Corporate VC arm of Sanofi focused on biotech and digital health investments. Direct peer — pharma-major CVC sourcing innovative therapeutics, comparable scale and stage focus.
• SR One (GSK): Corporate venture capital arm of GSK investing in biotech and therapeutics. Same model as Pharmstandard International — pharma-major-backed CVC supporting early-stage biotech with strategic parent backing.
• Novartis Venture Fund: Corporate venture capital arm of Novartis investing in innovative biotech and therapeutics. Directly comparable as a pharma-major CVC with a similar mission of sourcing early-stage innovation in therapeutic development.

Broad incumbents

• Johnson & Johnson Innovation: J&J's broad innovation and investment arm covering pharma, medtech, and consumer health. Larger-scale incumbent with broader scope but similar model of strategic corporate venturing in innovative medicine.

Regional players

• Rusnano: Russian state-owned technology and venture investment company. Comparable as a Russian-domiciled investor in innovative technology and biotech, with similar regional/sovereign-investor dynamics affecting Pharmstandard International.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments4 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pharmstandard International